**Initial Cohort**
Those ≥ 65 years with a fracture between April 1, 1991 and March 31, 2002 (n = 81,870) and a random sample (n = 142,077) of non-fracture subjects registered in the BCLHD over the same time period (n = 223,947)

**Bisphosphonate “Exposure” Cohort**
Those ≥ 65 years of age newly dispensed an oral bisphosphonate during the study index period – excluded those who were dispensed the drug within the previous 365 days (n = 26,518)

Identify nested cases within the bisphosphonate cohort – those with a diagnosis of UGIB and UGIB related death within 120 days of drug index date (n = 412)

Exclude – patients with previous diagnosis of UGIB within 365 days prior to index date of drug (n = 295)

**Outcome “case” group:**
UGIB or UGIB related death (n = 117)

**Internal control group:**
No UGIB or UGIB related death (n = 26,106)

*UGIB = upper gastrointestinal bleed*